One shot to fight blindness? gene therapy trial aims to replace frequent eye injections

This study is testing whether a single gene therapy injection can control wet age-related macular degeneration (a leading cause of blindness) as well as or better than the current standard of care, which requires eye injections every 1-4 months. About 284 participants, both new and previously treated, will receive either the experimental one-time gene therapy or regular aflibercept injections. The main goal is to see if the gene therapy helps people maintain or improve their vision over a year while reducing the burden of frequent treatments.